RT0307, RT2234, and RT8412 each align to a unique biological profile in ASD, targeting core symptom clusters. This same biology appears in other high-need populations, supporting expansion into ADHD, age-related decline, and inflammatory disorders.
Our pipeline is advancing across three parallel tracks, each built around a distinct biological domain. All programs are currently in IND-enabling studies, with first-in-human trials expected to begin in 2026.
The structure allows us to move efficiently from focused autism populations into broader neurodevelopmental and age-related conditions—while keeping safety, function, and family-centered outcomes at the core.
The biological pathways that drive autism symptoms—such as neuroinflammation, oxidative stress, mitochondrial dysfunction, and neurotransmitter imbalance—are also central to a wide range of other high-need conditions.
By targeting these shared mechanisms, each of our lead programs is positioned not only to meet urgent needs in autism, but also to expand into adjacent neurodevelopmental and neurodegenerative indications.